Phospho-CHK2 (Ser33 + Ser35)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 13908R
英文名称Phospho-CHK2 (Ser33 + Ser35)
中文名称磷酸化细胞周期检测点激酶2抗体
别 名Chk2 (phospho S33 + S35); p-Chk2 (phospho S33 + S35); bA444G7; CHK2 checkpoint homolog; CHK2_HUMAN; Serine/threonine-protein kinase Chk2; CDS 1; CDS1; Checkpoint kinase 2; Checkpoint like protein CHK2; Chek 2; Chek2; Chk 2; CHK2 checkpoint homolog (S. pombe); CHK2 checkpoint homolog; HuCds 1; HuCds1; LFS 2; LFS2; PP1425; RAD 53; RAD53; Rad53 homolog; Serine/threonine protein kinase Chk2.
规格价格100ul/1280元 购买 200ul/1980元 购买 大包装/询价
说 明 书100ul 200ul
研究领域肿瘤 细胞生物 信号转导 激酶和磷酸酶 表观遗传学
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
Phospho-CHK2 (Ser33 + Ser35)抗体交叉反应 Human,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-F=1:400-800 ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量61kDa
细胞定位细胞核
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human CHK2 isoform c around the phosphorylation site of Ser33 + Ser35:SS(p-S)Q(p-S)QG
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Phospho-CHK2 (Ser33 + Ser35)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]
Function:
Regulates cell cycle checkpoints and apoptosis in response to DNA damage, particularly to DNA double-strand breaks. Inhibits CDC25C phosphatase by phosphorylation on 'Ser-216', preventing the entry into mitosis. May also play a role in meiosis. Regulates the TP53 tumor suppressor through phosphorylation at 'Thr-18' and 'Ser-20'.
Subunit:
Homodimer. Homodimerization is part of the activation process but the dimer may dissociate following activation. Interacts with PML. Interacts with TP53. Interacts with RB1; phosphorylates RB1. Interacts with BRCA1. Interacts (phosphorylated at Thr-68) with MDC1; requires ATM-mediated phosphorylation of CHEK2. Interacts with TP53BP1; modulates CHEK2 phosphorylation at Thr-68 in response to ionizing radiation. Interacts with CDC25A; phosphorylates CDC25A and mediates its degradation in response to ionizing radiation. Interacts with CUL1; mediates CHEK2 ubiquitination and regulation.
Similarity:
Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. CHK2 subfamily.
Contains 1 FHA domain. Contains 1 protein kinase domain.
SWISS:
O96017
Gene ID:
11200
Phospho-CHK2 (Ser33 + Ser35)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
Phospho-CHK2 (Ser33 + Ser35)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 KPNA6 KPNA6蛋白抗体
合格 KR102 角蛋白相关蛋白10-2抗体
合格 KRBOX1 KRBOX1蛋白抗体
合格 KREMEN1 KREMEN1蛋白抗体
合格 KREMEN2 跨膜蛋白KREMEN2抗体
合格 KRT23 细胞角蛋白23抗体
合格 合格 CHK1 细胞周期检测点激酶1抗体
合格 KRT35 KRT35蛋白抗体
合格 CIB1 钙整合素结合蛋白1抗体
合格 KRT72 细胞角蛋白72抗体
合格 合格 KRT74 细胞角蛋白74抗体
合格 KRT85 细胞角蛋白85抗体
合格 CNR1 钙粘蛋白相关的神经受体1抗体
合格 KAP11.1 角蛋白相关蛋白11-1抗体
合格 KTEL1 骨髓增生异常综合征相关蛋白抗体
合格 KMO KMO蛋白抗体
合格 ODCp 精氨酸脱羧酶抗体
合格 LITD1 LITD1蛋白抗体
合格 L3MBTL2 致死因子恶性脑瘤样蛋白2抗体
合格 L3MBTL4 致死因子恶性脑瘤样蛋白4抗体
合格 KCNH4 KCNH4蛋白抗体
合格 KCNH5 KCNH5蛋白抗体
合格 KCNK2 钾离子通道蛋白2抗体
合格 KCNMB2 钙激活钾通道蛋白β2抗体
合格 KCNN1 电导钙激活钾通道蛋白1抗体
合格 KCNQ3 电压门控钾通道亚基Kv7.3抗体
合格 KCNRG 钾离子通道调节蛋白KCNRG抗体
合格 HCN4 环化核苷酸调控阳离子通道蛋白亚型4
合格 KCNV1 电压门控钾通道亚基Kv8.1抗体
合格 合格 KCNV2 电压门控钾通道Kv8.2抗体
合格 KCT2 角质形成细胞相关跨膜蛋白2抗体
合格 KCTD1 钾离子通道多聚体结构域蛋白1抗体
合格 KCTD14 钾离子通道多聚体结构域蛋白14抗体
合格 KCTD17 钾离子通道多聚体结构域蛋白17抗体
合格 ZIP Kinase 凋亡相关蛋白激酶3抗体
合格 KCTD19 钾离子通道多聚体结构域蛋白19抗体
合格 KCTD6 KCTD6蛋白抗体